相关实验视频

Updated: Jan 13, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

准生长激素受体以克服非小细胞肺癌治疗阻力

Arshad Ahmad^1,2,3, Reetobrata Basu¹, Caden Fyffe^1,4

¹Institute for Molecular Medicine and Aging and Diabetes Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, USA.

International journal of molecular sciences

|January 10, 2026

概括

增长激素 (GH) 信号驱动非小细胞肺癌 (NSCLC) 通过激活药物外流和上皮转介质过渡 (EMT) 来驱动治疗抵抗. 用抗体向GH受体 (GHR) 提高了NSCLC模型中的化疗疗效率.

科学领域:

在瘤学瘤学.
内分泌学在内分泌学.
分子生物学分子生物学

背景情况:

肺癌 (LC) 是癌症死亡的主要原因,非小细胞肺癌 (NSCLC) 是最常见的亚型.
增长激素 (GH) 信号与各种癌症的瘤进展和治疗耐药性有关.
GH受体 (GHR) 表达在NSCLC中升高,这表明它可能在疾病的攻击性和治疗结果中发挥作用.

研究的目的:

研究GH信号对NSCLC治疗耐药性和瘤进展的影响.
探索GHR表达与患者存活率和耐治疗途径之间的相关性.
评估GHR对抗作用在克服NSCLC化学抵抗方面的有效性.

主要方法:

对NSCLC患者数据的综合转录组分析.
在体外实验中,使用用GH和GHR抗剂治疗的NSCLC细胞系进行了实验.
评估与药物外流 (ABC输送器) 和上皮转介质转换 (EMT) 相关的基因表达.

主要成果:

在NSCLC患者中,高瘤GHR表达与治疗耐药基因的整体存活率降低和上调相关.
GH治疗通过激活ABC转运体和EMT通路,促进NSCLC细胞系中的化学抵抗.
维索曼与GHR的对抗作用抵消了GH诱导的化学抵抗,并在体外显著提高了化疗疗效.

结论:

GH信号传递有助于NSCLC中的侵略性和耐治疗性表型.
GHR对抗是一种潜在的治疗策略,可以提高NSCLC的化疗敏感性.
针对 GHR 需要在临床前和临床环境中对 NSCLC 治疗进行进一步的研究.

关键词:

西斯普拉丁 (cisplatin) 是一种制剂.增长激素增长激素的使用方法增长激素受体增长激素受体肺癌是一种肺癌.子视觉子是什么意思治疗耐药性治疗耐药性

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...